Figure 4
Figure 4. Binding of CLL mAb with stereotypic IGHV1-69, IGHD3-16, and IGHJ3 rearrangements colocalizes with MYHIIA. (A) HEp-2 cells stained with CLL068 antibody (green) and anti-MYHIIA antibody (red) were visualized by confocal microscopy separately and merged together (overlap in yellowish orange). Untreated or blebbistatin-treated SNB19 cells were stained with CLL068 antibody (green) and (B) anti-MYHIIA antibody (red) or (C) phalloidin-stained F-actin (red). Cells were visualized by confocal microscopy separately and merged together.

Binding of CLL mAb with stereotypic IGHV1-69, IGHD3-16, and IGHJ3 rearrangements colocalizes with MYHIIA. (A) HEp-2 cells stained with CLL068 antibody (green) and anti-MYHIIA antibody (red) were visualized by confocal microscopy separately and merged together (overlap in yellowish orange). Untreated or blebbistatin-treated SNB19 cells were stained with CLL068 antibody (green) and (B) anti-MYHIIA antibody (red) or (C) phalloidin-stained F-actin (red). Cells were visualized by confocal microscopy separately and merged together.

Close Modal

or Create an Account

Close Modal
Close Modal